ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
European Commission approved Amgen's IMDYLLTRA for advanced small cell lung cancer based on Phase 3 DeLLphi-304 trial showing a 40% reduction in mortality risk compared to chemotherapy.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
European Commission approval for advanced small cell lung cancer
Importance:8/10
Sentiment:
0.85
regulatory_approvaloncologyEuropePhase_3_successIMDYLLTRA
Related Companies
Read the original article
Published by PR Newswire Biotech on June 3, 2026 1:43 PM